The correlations between serum amphiregulin and other clinicopathological factors in colorectal cancer

Chayangsu, Chawalit; Khunsri, Siriporn; Sriuranpong, Virote; Tanasanvimon, Suebpong

doi:10.21037/jgo.2017.08.15

Cited by 9 publications

(9 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AREG, a member of the EGF family, was reported as having high expression in CRC and was associated with tumor invasion, liver metastasis, and lower survival 33 . Recently, serum levels of AREG higher than 25 pg/mL, evaluated in 120 CRC patients, was significantly associated with liver and peritoneal metastasis 34 . The authors also found high levels of serum AREG associated with distant metastasis, mucinous histological grade, lymphovascular and perineural invasion.…”

Section: Discussionmentioning

confidence: 99%

“…The authors also found high levels of serum AREG associated with distant metastasis, mucinous histological grade, lymphovascular and perineural invasion. In serum from rectal cancer (N = 53) patients, high expression of AREG was detected in 24.5% of cases 34 . In our sample set, two cases presented high levels of AREG (10 and 12 pg/mL) and none of them presented distant metastasis or other clinical pathological features as described by Chayangsu et al .…”

Section: Discussionmentioning

confidence: 99%

“…In our sample set, two cases presented high levels of AREG (10 and 12 pg/mL) and none of them presented distant metastasis or other clinical pathological features as described by Chayangsu et al . (2017) 34 . However, our sample set was restricted to 14 LARC cases.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Locally advanced rectal cancer transcriptomic-based secretome analysis reveals novel biomarkers useful to identify patients according to neoadjuvant chemoradiotherapy response

Canto

Cury

Barros-Filho

et al. 2019

Sci Rep

View full text Add to dashboard Cite

Most patients with locally advanced rectal cancer (LARC) present incomplete pathological response (pIR) to neoadjuvant chemoradiotherapy (nCRT). Despite the efforts to predict treatment response using tumor-molecular features, as differentially expressed genes, no molecule has proved to be a strong biomarker. The tumor secretome analysis is a promising strategy for biomarkers identification, which can be assessed using transcriptomic data. We performed transcriptomic-based secretome analysis to select potentially secreted proteins using an in silico approach. The tumor expression profile of 28 LARC biopsies collected before nCRT was compared with normal rectal tissues (NT). The expression profile showed no significant differences between complete (pCR) and incomplete responders to nCRT. Genes with increased expression (pCR = 106 and pIR = 357) were used for secretome analysis based on public databases (Vesiclepedia, Human Cancer Secretome, and Plasma Proteome). Seventeen potentially secreted candidates (pCR = 1, pIR = 13 and 3 in both groups) were further investigated in two independent datasets (TCGA and GSE68204) confirming their over-expression in LARC and association with nCRT response (GSE68204). The expression of circulating amphiregulin and cMET proteins was confirmed in serum from 14 LARC patients. Future studies in liquid biopsies could confirm the utility of these proteins for personalized treatment in LARC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Locally advanced rectal cancer transcriptomic-based secretome analysis reveals novel biomarkers useful to identify patients according to neoadjuvant chemoradiotherapy response

Canto

Cury

Barros-Filho

et al. 2019

Sci Rep

View full text Add to dashboard Cite

show abstract

“…These findings underline the potential dual role of the IL-33/ST2 axis in colon cancer (63) and the need for further analysis of this pathway in different CRC models. AREG is another important molecule that regulates cancer cell proliferation, invasion and angiogenesis (64) and has been proposed as a prognostic marker in CRC (65). AREG upregulation is associated with increased migration and invasion of CRC cells which is essential for metastasis [(66, 67); Figure 1, left middle panel].…”

Section: Ilc2s In Cancers Of the Gastrointestinal Systemmentioning

confidence: 99%

ILC2s: New Actors in Tumor Immunity

et al. 2019

View full text Add to dashboard Cite

Innate lymphoid cells (ILCs) represent the most recently identified family of innate lymphocytes that act as first responders, maintaining tissue homeostasis and protecting epithelial barriers. In the last few years, group 2 ILCs (ILC2s) have emerged as key regulators in several immunological processes such as asthma and allergy. Whilst ILC2s are currently being evaluated as novel targets for immunotherapy in these diseases, their involvement in tumor immunity has only recently begun to be deciphered. Here, we provide a comprehensive overview of the pleiotropic roles of ILC2s in different tumor settings. Furthermore, we discuss how different therapeutic approaches targeting ILC2s could improve the efficacy of current tumor immunotherapies.

show abstract

“…EGFR ligands, epiregulin (EREG) and amphiregulin (AREG) are overexpressed in CRC [30,31] . EREG and AREG expressions in mRNA, tumor protein and plasma protein levels are associated with poor prognosis in CRC [31][32][33] . In vitro studies demonstrated their autocrine activation and reduction of cetuximab effect in AREG and EREG gene silencing CRC cells [34,35] .…”

Section: Other Biomarkersmentioning

confidence: 99%

Molecular biomarkers in current management of metastatic colorectal cancer

Tanasanvimon¹

2018

JCMT

Self Cite

View full text Add to dashboard Cite

Over the past two decades, the treatment outcomes in metastatic colorectal cancer (mCRC) have been remarkably improved, largely from the evolution of systemic therapy. Also, the molecular biomarkers have played a major role in this improvement by their predictive value in current treatment paradigm in mCRC. Currently, extended RAS mutation analysis is required for consideration of anti-epidermal growth factor receptor therapy in patients with mCRC. Several uncommon gene alterations have emerged as the potential targets for their matched molecular targeted therapy. Although, most patients with mCRC do not derive benefit from immunotherapy. By using microsatellite instability or mismatch repair test, we are now able to identify a small subgroup of patients with mCRC who have a very good response to immune checkpoint inhibitors. With the increasing number of required biomarkers in mCRC management, multiplex gene panel testing is now replacing single gene testing strategy. In patients accessible to matched molecular targeted therapy, especially for clinical trials, the comprehensive genomic profiling might be the preferred testing method. Although, it is potentially benefit in mCRC treatment, the liquid biopsy is not yet clinically applicable. The optimal utilization of molecular biomarker testing is required for best treatment outcomes in individual patients.

show abstract

The correlations between serum amphiregulin and other clinicopathological factors in colorectal cancer

Abstract: High serum AREG was associated with advanced diseases and poor pathologic factors in CRC. It is potentially a prognostic marker in CRC.

Cited by 9 publications

References 9 publications

Locally advanced rectal cancer transcriptomic-based secretome analysis reveals novel biomarkers useful to identify patients according to neoadjuvant chemoradiotherapy response

Locally advanced rectal cancer transcriptomic-based secretome analysis reveals novel biomarkers useful to identify patients according to neoadjuvant chemoradiotherapy response

ILC2s: New Actors in Tumor Immunity

Molecular biomarkers in current management of metastatic colorectal cancer

Contact Info

Product

Resources

About